Log in to your Inderes Free account to see all free content on this page.
Cantargia
1.937
SEK
-35 %
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1,314 following
cantargia.com
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CANTA
Daily low / high price
1.883 / 2.08
SEK
Market cap
355.8M SEK
Turnover
4.35M SEK
Volume
2.2M
Latest videos
Financial calendar
Interim report
15.11.2024
Extraordinary general meeting
02.12.2024
Annual report
21.02.2025
Interim report
13.05.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Fjärde AP-fonden | 9.9 % | 9.9 % |
| Första AP-Fonden | 7.1 % | 7.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Cantargia, Audiocast with teleconference, Q3'24
Notice of extraordinary general meeting in Cantargia AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Cantargia resolves on a rights issue of approximately SEK 170 million
Cantargia presents promising preclinical results on nadunolimab with antibody-drug conjugates at major immuno-oncology conference
Cantargia AB: Cantargia will present at the BioStock Life Science Summit, November 21
Invitation to presentation of Cantargia’s interim report January – September 2024
Cantargia reports new results from clinical studies investigating nadunolimab in several forms of cancer; supporting ongoing strategies
Cantargia reports new positive results on biomarkers and safety in CAN10 phase 1 clinical study
Cantargia’s strong Phase 2 clinical data in pancreatic cancer with nadunolimab published in Clinical Cancer Research
Cantargia reports start of multiple dosing part in CAN10 phase 1 clinical trial
Cantargia presents new results at EADV 2024 highlighting the potential of CAN10 treatment in dermatology
Cantargia presents positive results at ESMO Congress 2024 showing benefit of nadunolimab combination therapy in cancer after relapse on PD1-inhibitors
Cantargia: new data from two clinical studies strongly support nadunolimab efficacy after relapse on PD1-inhibitors
Redeye: Cantargia Q2 2024 - CAN10 Proof-of-Mechanism
